<DOC>
	<DOCNO>NCT01061294</DOCNO>
	<brief_summary>The purpose study ass efficacy , predictability safety Advanced CustomVue™ iLASIK procedure ( WaveScan WaveFront® System , STAR S4 IR™ Excimer Laser System IntraLase™ FS System ) . Patient data collect electronically analyze determine improvement postoperative visual acuity , visual quality residual error .</brief_summary>
	<brief_title>Evaluation Outcomes Using AMO Advanced Customvue™ iLasik Procedure</brief_title>
	<detailed_description />
	<criteria>1. subject must male female , race , least 21 year old time preoperative examination ; 2. eye must BSCVA 20/20 good ; 3. eye must manifest refractive error 0.50 D 6.00 D , cylinder component 3.00 D , maximum manifest spherical equivalent 6.00 D ; 4. eye must minimum pupil size least 6.0mm dim illumination wavescan ; 5. eye must demonstrate refractive stability confirm clinical record previous glass . Refractive stability shall document change less equal 0.50 diopter ( sphere cylinder ) exam least 12 month prior baseline examination . The astigmatic axis must also within 15 degree eye cylinder great 0.50 D ; 6. subject willing capable return followup examination duration study . 1. subject use concurrent topical systemic medication may impair heal , include limited : antimetabolite , isotretinoin ( Accutane® ) within 6 month treatment , amiodarone hydrochloride ( Cordarone® ) within 12 month treatment ; NOTE : The use topical systemic corticosteroid , whether chronic acute , deem adversely affect heal subject use medication specifically exclude eligibility . 2. subject history follow medical condition , condition could affect wound healing : collagen vascular disease , autoimmune disease , immunodeficiency disease , ocular herpes zoster simplex , endocrine disorder ( include , limited unstable thyroid disorder diabetes ) , lupus , rheumatoid arthritis ; NOTE : The presence diabetes ( either type 1 2 ) , regardless disease duration , severity control , specifically exclude subject eligibility . 3. subject must history prior intraocular corneal surgery ( include cataract extraction ) , active ophthalmic disease abnormality ( include , limited , blepharitis , recurrent corneal erosion , dry eye syndrome , neovascularization &gt; 1mm limbus ) , clinically significant lens opacity , clinical evidence trauma ( include scar ) , evidence glaucoma propensity narrow angle glaucoma either eye ; NOTE : This include subject open angle glaucoma , regardless medication regimen control . . 4. subject must evidence keratoconus , corneal irregularity , abnormal videokeratography either eye ; 5. subject know sensitivity inappropriate responsiveness medication use postoperative course ; 6. patient achieve Iris registration time wavescan ; 7. patient seek monovision .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Assess efficacy , predictability safety Advanced CustomVue™ iLASIK procedure .</keyword>
</DOC>